ERBB2 and breast cancer: Tan et al. [34] also found that by inhibiting PKCα or Src by chemical inhibitors, dominant-negative mutants or siRNA, uPAR expression decreased and there was a reduction in cancer cell invasion in HER2 overexpressing BC cell lines.